busulphan in CML
Last reviewed 01/2018
Busulphan is a second line treatment for CML and is reserved for patients who are resistant to hydroxycarbamide (former British Approved Name, hydroxyurea)or are poorly compliant.
You are currently on the
Australia version of this site. To see content specific to your location,
please choose your country or region.
GPnotebook no longer supports Internet Explorer. To ensure the site functions as intended, please
upgrade your browser. Microsoft is encouraging users to upgrade to its more modern
Edge browser for improved security and functionality.